Fulya İLHAN, Atilla SEMERCİÖZ, Hayreddin YEKELER, Nusret AKPOLAT, Seyfettin YAHŞİ, Ahmet GÖDEKMERDAN

Determination of Nuclear Matrix Protein 22 Levels in Cystitis, Urothelial Dysplasia and Urothelial Carcinoma

Urothelial carcinomas (UC) are the most common cancer type of the urinary system. The early diagnosis and treatment of UC are very important.The aim of this study was to evaluate the importance of the nuclear matrix protein 22 (NMP22) in early diagnosis of UC and to present its variation in cystitis and urothelial dysplasia (UD). Twenty patients with UC, 20 patients with UD and 20 patients with cystitis diagnosed by urinary cytological examination were enrolled in this study. In addition, 20 healthy people constituted the control group. Urine samples were collected from all patients and control subjects for NMP22 measurement and cytology. Those who were diagnosed with cytological malignancy were also histologically evaluated for accuracy. Additionally, the NMP22 levels of all participants were measured by ELISA. When compared according to the cytologic results, the NMP22 levels in the UC group were found significantly higher compared to those having UD, cystitis and control group (P < 0.05). No statistically significant difference was found between other groups. It has been concluded that NMP22 can be used in the early diagnosis and determination of recurrences in UC. However, as the NMP22 level may be increased by other factors such as UD, cystitis, bladder stones and non-urothelial carcinomas of bladder, it is suggested urinary cytology that showed be jointly used with NMP22 measuring.

Anahtar Kelimeler:

Nuclear matrix protein 22, urinary cytology, urothelial carcinoma, urothelial dysplasia, cystitis

Determination of Nuclear Matrix Protein 22 Levels in Cystitis, Urothelial Dysplasia and Urothelial Carcinoma

Keywords:

Nuclear matrix protein 22, urinary cytology, urothelial carcinoma, urothelial dysplasia, cystitis,

PDF

___

1. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. Cancer J Clin; 45: 8-30, 1995.
2. Stampfer DS, Carpinito GA, Rodriguez-Villanueva et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urology 159: 394-8, 1998.
3. Carpinito GA, Stadler WM, Briggman JV et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urology 156: 1280-5,1996.
4. Chen YT, Hayden CL, Marchand KJ et al. Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumour marker. J Urology 158: 1899-1901,1997.
5. Soloway MS, Briggman JV, Carpinito GA et al. Use of a new tumour marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urology 156: 363-7, 1996.
6. Berezney R, Coffey DS. Identification of a nuclear matrix protein. Biochem Biophys Res Commun 60: 1410-17, 1991.
7. Lakshmanan Y, Subong ENP, Partin AW. Differential nuclear matrix protein expression in prostate cancers: Correlation with pathologic state. J Urology 159: 1354-58, 1997.
8. Partin AW, Briggman JV, Subong ENP et al. Preliminary immunohistochemical characterization of a monoclonal antibody (pro: 4-216) prepared from human prostate cancer nuclear matrix proteins. Urology 50:800-8, 1997.
9. Keesee SK, Briggman JV, Thil G et al. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukary Gene Exp 6: 189- 214,1996.
10. Carpitino GA, Stadler WM, Briggman JV et al. Urinary nuclear marix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 156:1280-1285, 1996.
11. Curry JL, Wojcik EM. The effects of the current World Health Organisation/ International Society of Urologic Pathologists bladder neoplasm classification system on urine cytology results. Cancer Cytopathol 96: 140-5, 2002.
12. Huang S, Rhee E, Patel H et al. Urinary NMP22 and renal cell carcinoma. Urology 55:227-30, 2000.
13. Sharma S, Zippe CD, Pandrangi L et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 162:53-7, 1999.
14. Friedrich MG, Hellstern A, Toma MI et al. Are false positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumour recurrence? Eur Urol 43:146-51, 2003